JB Pharma Q4 Results: Net profit rises 4% to Rs 88 crore
Operating cash flow improved in FY23 to Rs 626 crores as compared to Rs 170 crores in FY22, strongly aided by the higher proportion of India business and a strong focus on working capital management, which includes inventory and receivables.
